Vol 7: Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer1.Report as inadecuate



 Vol 7: Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer1.


Vol 7: Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer1. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 7: Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer1.
This article is from Translational Oncology, volume 7.AbstractBACKGROUND: Efficacy of second-line chemotherapy in platinum-pretreated non–small cell lung cancer NSCLC is poor. This study investigated efficacy of computed tomography–guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection CT-PFNECII combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. PATIENTS: Between October 2011 and July 2013, 34 eligible patients were randomly assigned to receive either CT-PFNECII combined with second-line chemotherapy combination group, n = 17 or second-line chemotherapy alone chemotherapy group, n = 17. The primary end points were the proportions of patients who achieved an overall response rate ORR and disease control rate DCR. Secondary end points were median survival and progression-free survival PFS. RESULTS: The ORR and DCR in the combination group were significantly higher than in the chemotherapy group 23.53% vs 11.76% for ORR, P .01; and 58.82% vs 35.29% for DCR, P .01. Compared with patients in the chemotherapy group, patients in the combination group had significantly longer PFS 5.4 months vs 3.0 months, P .01 and median survival 9.5 months vs 5.3 months, P .01. CONCLUSIONS: CT-PFNECII combined with second-line chemotherapy provided a higher response rate and improved survival than second-line chemotherapy for patients with platinum-pretreated stage IV NSCLC.



Author: Niu, Qi; Wang, Wei; Li, Qian; Li, Yong; Ruden, Douglas M.; He, Baoming

Source: https://archive.org/







Related documents